Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes

References

• De Franchis R. Portal hypertension III. Proceedings of the third Baveno international consensus workshop of definitions, methodology and therapeutic strategies. London: Blackwell Science Ltd; 2001.
   Google Scholar
• Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056–9
   PubMed Web of Science ®Google Scholar
• Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7: 648–53
   PubMed Web of Science ®Google Scholar
• Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 1401–7
   PubMed Web of Science ®Google Scholar
• Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114: 869–73
   PubMedGoogle Scholar
• Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 1997; 26: 34–9
   PubMedGoogle Scholar
• Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38: S54–68
   PubMed Web of Science ®Google Scholar
• Albillos A, Lledo JL, Rossi I, Perez-Paramo M, Tabuenca MJ, Banares R, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995; 109: 1257–65
   PubMed Web of Science ®Google Scholar
• Debernardi-Venon W, Barletti C, Alessandria C, Marzano A, Baronio M, Todros L, et al. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci 2002; 47: 401–4
   PubMedGoogle Scholar
• Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121: 389–95
   PubMed Web of Science ®Google Scholar
• Frishman WH. Carvedilol. N Engl J Med 1998; 339: 1759–65
   PubMed Web of Science ®Google Scholar
• Forrest EH, Bouchier IAD, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996; 25: 909–15
   PubMed Web of Science ®Google Scholar
• Baňares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30: 79–83
   PubMed Web of Science ®Google Scholar
• Tripanti D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2002; 16: 373–80
   PubMedGoogle Scholar
• Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol 2004; 99: 1953–8
   PubMed Web of Science ®Google Scholar
• De BK, Das D, Sen S, Biswas PK, Mandal SK, Majumdar D, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002; 17: 183–9
   PubMedGoogle Scholar
• Baňares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002; 36: 1367–73
   PubMed Web of Science ®Google Scholar
• Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, et al. “A la carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36: 1361–6
   PubMed Web of Science ®Google Scholar
• Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 1200–5
   PubMed Web of Science ®Google Scholar
• Wiest R, Groszmann R. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 411–26
   PubMed Web of Science ®Google Scholar
• Reichen J. Portal hypertension: cytokines and endothelins. Hepatogastroenterology 1999; 46(Suppl 2)1434–6
   PubMedGoogle Scholar
• Genesca J, Gonzales A, Sugura R, Catalan R, Marti R, Varela E, et al. Interleukin 6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999; 94: 169–77
   PubMed Web of Science ®Google Scholar
• Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 89: 273–93
   PubMed Web of Science ®Google Scholar
• Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996; 110: 534–48
   PubMed Web of Science ®Google Scholar
• Giron-Gonzales JA, Martinez-Sierra C, Rodriguez-Ramos C, Macias MA, Rendon P, Diaz F, Fernandez-Gutierrez C, et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver International 2004; 24: 437–45
   PubMedGoogle Scholar
• Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver disease. Gastroenterology 1992; 103: 264–74
   PubMed Web of Science ®Google Scholar
• Heller J, Sogni P, Barriere E, Tazi KA, Chauvelot-Moachon L, Guimont MC, et al. Effect of lipopolysaccharide on TNF-α production, hepatic NOS2 activity and hepatic toxicity in rats with cirrhosis. J Hepatol 2000; 33: 376–81
   PubMed Web of Science ®Google Scholar
• Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993; 11: 767–804
   PubMed Web of Science ®Google Scholar
• Volpes R, van den Oord JJ, Desmet V. Hepatic expression of intercellular adhesion molecule-1 (ICAM-1) in viral hepatitis B. Hepatology 1990; 12: 148–54
   PubMedGoogle Scholar
• Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2061–101
   PubMedGoogle Scholar
• Yamaguchi M, Tokushige K, Haruta I, Yamauchi K, Hayashi N. Analysis of adhesion molecules in patients with idiopathic portal hypertension. J Gastroenterol Hepatol 1999; 14: 364–9
   PubMedGoogle Scholar
• Blum A, Yeganeh S, Peleg A, Vigder F, Kryuger K, Khatib A, et al. Endothelial function in patients with sickle cell anemia during and after sickle cell crises. J Thromb Thrombolysis 2005; 19: 83–6
   PubMed Web of Science ®Google Scholar
• Lupattelli G, Marchesi S, Lombardini R, Roscini AR, Trinca F, Gemelli F, et al. Artichoke juice improves endothelial function in hyperlipemia. Life Sci 2004; 76: 775–82
   PubMed Web of Science ®Google Scholar
• Marchesi S, Lupattelli G, Lombardini R, Roscini AR, Siepi D, Vaudo G, et al. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J Clin Pharm Ther 2003; 28: 419–24
   PubMed Web of Science ®Google Scholar
• Giron-Gonzales JA, Martinez-Sierra C, Rodriguez-Ramos C, Rendon P, Macias MA, Fernandez-Gutierrez C, et al. Adhesion molecules as a prognostic marker of liver cirrhosis. Scand J Gastroenterol 2005; 40: 217–24
   PubMedGoogle Scholar
• Navasa M, Follo A, Filella X, Jimenez W, Francitorra A, Planas R, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 1227–32
   PubMed Web of Science ®Google Scholar
• Giron-Gonzales JA, Rodriguez-Ramos C, Elvira J, Galan F, Del Alamo CF, Diaz F, et al. Serial analysis of serum and ascitic fluid levels of soluble adhesion molecules and chemokines in patients with spontaneous bacterial peritonitis. Clin Exp Immunol 2001; 123: 56–61
   PubMedGoogle Scholar
• Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-α and hyperdynamic circulation. Scand J Gastroenterol 1996; 31: 500–5
   PubMed Web of Science ®Google Scholar
• Binay KD, Debasish D, Sambit S, Pranab KB, Sanjay KM, Debasis M, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002; 17: 183–9
   PubMedGoogle Scholar
• Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzales B, Minana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004; 40: 757–65
   PubMed Web of Science ®Google Scholar
• Abraldes LG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long term prognosis of cirrhosis. Hepatology 2003; 37: 902–8
   PubMed Web of Science ®Google Scholar
• D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332–53
   PubMed Web of Science ®Google Scholar
• Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39: 280–2
   PubMed Web of Science ®Google Scholar
• Abillos A, Lledo JL, Rossi I, Perez-Paramo M, Tabuenca MJ, Banares R, et al. Continuous prazosin administration in cirrhotic patients: effects on portal haemodynamics and on liver and renal function. Gastroenterology 1995; 109: 1257–65
   PubMedGoogle Scholar
• Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999; 30: 479–84
   PubMed Web of Science ®Google Scholar
• Dupont AG, Neipen P, Taeymans Y, Ingels M, Piepsz A, Bossuyt AM, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharm 1987; 10(Suppl 11)130–6
   Google Scholar